Recent years have seen a surge in psychiatric diseases, which has resulted in considerable disease
distress and considerably decreased living conditions. Many considerable synthetic medications have
been used to treat these illnesses throughout the years, but they have been found to have limited
effects and substantial recurrence risks in many individuals. Mental illnesses such as depression
and anxiety are persistently on the rise around the world, posing serious challenges to the affected
person’s and their family members’ personal lives. There is mounting evidence that suggests the gut–
brain axis (GBA) contributes to the genesis and development of psychiatric diseases. This review
focuses on contemporary dietary therapies such as Mediterranean diets and dietary supplements
and emphasizes nutrition’s critical role in psychiatric care through the GBA. Several research have
indicated that dietary quality affects mental health because it controls metabolic processes, has
anti‑inflammatory and antiapoptotic characteristics, and promotes neurogenesis and synaptogenesis.
This study demonstrates many dietary components, their relationships to depression, and how they
work. The use of dietary recommendations to support mental health appears to be a novel, affordable,
useful, nonpharmacological intervention for people with mental problems.

Background: Tramadol has a high potential for misuse resulting in cognitive impairment.
Zingiber officinale, however, possesses neuroprotective qualities. Objective: Microscopically
assessed hippocampal CA1 and CA3 following Z. officinale and tramadol treatment.
Materials and Methods: Two milliliters/kilogram of distilled water was given to Group 1,
Groups 2–5 were administered 50 mg/kg of tramadol while Group 3 was also administered 12.5 mg/
kg of naltrexone, and Groups 4 and 5 were also administered 500, and 1000 mg/kg ethanol extract of
Z. officinale (EEZO), respectively, orally for 21 days. The rats were euthanized and their brains were
collected, fixed in 10% formal saline, and processed routinely using crystal fast violet (CFV) stain for
the demonstration of Nissl substance, glial fibrillary acidic protein (GFAP) for the demonstration of
astrocytes, and Hematoxylin and Eosin for general histoarchitecture and estimation of cell number and
volume using physical dissector and Cavalieri estimator, respectively. Results: CFV stain revealed
alterations in regions of CA1 and CA3 of the hippocampus presenting as indistinct staining intensity
and peripheral Nissl substance accumulation in the tramadol‑treated group. GFAP revealed numerous
reactive astrocyte processes. The area of reactive astrocytes remarkably increased (P < 0.05) and
the intensity of the Nissl substance remarkably reduced in the tramadol-exposed group. When
compared to the control, the tramadol-exposed group’s hippocampal volume considerably (P < 0.05)
decreased (coefficient of error [CE] =0.050). The tramadol treatment group (CE = 0.090) relative to
the control group (CE = 0.060) showed a striking decrease (P < 0.05) in the number of pyramidal
cells in the CA3 region. The tramadol treatment group (CE = 0.090) compared to the control
group (CE = 0.060) showed a striking decrease (P < 0.05) in the number of pyramidal cells in the
CA3 region. Tramadol toxicity was attenuated in the groups treated with EEZO in a dose-dependent
manner. Conclusion: Z. officinale possesses a potential neuroprotective effect against tramadol‑induced
neurotoxicity.